SIGA Reports Q1 2026 Results; Lumpy Revenue, No Catalyst

What happened

SIGA reported financial results for Q1 2026, the period ending March 31, 2026. While the press release provides no specific figures, historical patterns suggest minimal product deliveries in the quarter, consistent with the lumpy government contract revenue that defines the business. The company's core BARDA 19C contract is largely exercised, and no new material orders were announced, leaving future revenue dependent on discretionary option exercises or new contracts. Meanwhile, headwinds from Tembexa competition and weak mpox efficacy data persist. The stock trades at ~5.5x trailing EPS with net cash, but the lack of near-term catalysts reinforces the thesis that SIGA is a short-duration annuity with policy-driven risk.

Implication

Valuation is cheap on trailing earnings, but future cash flows are highly dependent on BARDA follow-on contracts and international orders. The Q1 report likely confirms the lumpy, declining revenue trajectory. Risk-tolerant investors can hold for potential policy-driven upside, but conservative investors should wait for clearer contract visibility. The single-asset, single-customer concentration limits the margin of safety despite net cash.

Thesis delta

No material change from prior thesis. The Q1 2026 report reinforces the existing narrative of lumpy government-dependent revenue with no new contract catalysts. The thesis remains a potential buy for risk-tolerant investors comfortable with policy risk, but the lack of positive news keeps the stance cautious.